Ulcerative colitis (UC) is a chronic inflammatory bowel disease that causes inflammation and ulcers in the lining of the colon and rectum. Symptoms can include diarrhea, rectal bleeding, abdominal pain, urgency, and fatigue. When conventional treatments do not adequately control moderate to severe disease, biologic therapies may be considered. Biologics target specific immune pathways involved in intestinal inflammation and can help achieve and maintain remission for many people with ulcerative colitis.
Biologic medicines are therapies produced using biological processes and designed to target specific components of the immune response.
Depending on the medication, biologics may block inflammatory proteins or interfere with immune-cell activity.
Potential goals of treatment include:
Several biologic classes are used for ulcerative colitis.
Tumor necrosis factor (TNF) is an inflammatory protein involved in intestinal inflammation.
TNF inhibitors used for UC include:
These medications can reduce inflammation and help maintain remission in appropriate patients.
Vedolizumab is a gut-selective biologic that targets an integrin involved in the movement of inflammatory immune cells into intestinal tissue.
Because its activity is focused largely on the gastrointestinal tract, it has a distinct mechanism from systemic biologic therapies.
Some biologics target inflammatory signaling involving interleukins.
Ustekinumab blocks pathways involving IL-12 and IL-23, while newer therapies targeting IL-23 are also used for certain patients with moderate to severe ulcerative colitis.
The appropriate medication depends on disease characteristics and previous treatment history.
Biologics may be considered for people with moderate to severe ulcerative colitis when other treatments have not provided sufficient disease control or when biologic therapy is appropriate based on the individual's clinical situation.
Factors considered may include:
Treatment decisions are individualized.
Depending on the medication, treatment may involve:
Some treatments begin with more frequent doses followed by maintenance therapy at longer intervals.
The exact schedule varies by medication.
Effective biologic therapy may help:
Response varies, and treatment may need to be adjusted if disease activity persists.
Because biologics influence immune activity, they may increase susceptibility to infections.
Potential side effects can include:
Specific risks differ between medications.
Healthcare providers generally review infection risks before beginning biologic therapy.
Depending on the medication and individual circumstances, screening may include:
Certain vaccines may need to be administered before immunosuppressive treatment begins.
Regular follow-up is important to determine whether treatment is controlling intestinal inflammation.
Monitoring may include:
Treatment may be continued, adjusted, or switched depending on the response.
Biologics may sometimes be used alongside other treatments, including aminosalicylates, immunomodulators, corticosteroids, or other advanced therapies.
Long-term corticosteroid use is generally avoided when possible because of its potential complications. The treatment goal is often to achieve sustained disease control with an appropriate maintenance therapy.
Selection depends on factors such as:
A gastroenterologist can help determine which therapy is most appropriate.
Urgent medical evaluation may be necessary for:
These symptoms can indicate a serious flare or complication requiring prompt treatment.
Biologics have become an important treatment category for moderate to severe ulcerative colitis. TNF inhibitors, integrin-targeted therapies, and interleukin-targeted biologics work through different immune pathways to reduce intestinal inflammation and help maintain remission. Appropriate screening, individualized medication selection, and regular monitoring can help maximize treatment benefits while managing potential risks.